WHO ICTRP trial
A 12-WEEK, PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY TO…
EUCTR2006-003577-27-EE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2006-003577-27-EE |
|---|---|
| Public title | A 12-WEEK, PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF PH-797804, ADMINISTERED ORALLY ONCE DAILY IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS. - na |
| Scientific title | A 12-WEEK, PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF PH-797804, ADMINISTERED ORALLY ONCE DAILY IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS. - na |
| Primary sponsor | Pfizer Luxembourg SARL Branch Office Estonia |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Czech Republic;Estonia;Spain |
| Conditions | Treatment of rheumatoid arthritis (RA) MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis |
| Interventions | Product Code: PH-797804 Pharmaceutical Form: Capsule* CAS Number: 586414-48-4 Current Sponsor code: PH-797804 Other descriptive name: S(-)-3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2H)-yl]-N,4-dimethylbenzamide… |
| Registration date | Sep 29, 2006 |
| Target size | 290 |
| Secondary IDs | A6631007 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: